FOUNDATION MEDICINE (FMI) Covered Calls

FOUNDATION MEDICINE covered calls Foundation Medicine Inc is a commercial-stage company focused on fundamentally changing the way patients with cancer are treated. Its first clinical product, FoundationOne, is only commercially available product designed for use in routine patient care.

You can sell covered calls on FOUNDATION MEDICINE to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for FMI (prices last updated Fri 4:16 PM ET):

FOUNDATION MEDICINE (FMI) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
136.95 +0.05 136.75 136.90 893K - 5.1B
Covered Calls For FOUNDATION MEDICINE (FMI)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Aug 17 135 1.95 134.95 0.0% 0.0%
Nov 16 135 1.95 134.95 0.0% 0.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Foundation Medicine, Inc. is a commercial-stage company, which focuses on fundamentally changing the way patients with cancer are treated. The company's first clinical product, FoundationOne, is a commercially available comprehensive molecular information product designed for use in the routine care of patients with cancer. It provides comprehensive cancer diagnostic test that represents this critical step toward individualized cancer care by helping physicians recommend treatment options for each patient based on the molecular subtype of their cancer. The company's proprietary molecular information platform generates actionable genomic information about a patient's individual cancer, enabling physicians to optimize treatments in clinical practice and enabling biopharmaceutical companies to develop targeted oncology therapies more effectively. Foundation Medicine was founded by Alexis Borisy, Eric Lander, Todd Golub, Levi Garraway and Matthew Meyerson in November 2009 and is headquartered in Cambridge, MA.